CRISPR isn’t just a breakthrough in science — it’s the center of a $400 million intellectual property dispute.

What’s happening?
UC Berkeley is appealing to reclaim broad U.S. patent rights over CRISPR, the revolutionary gene-editing tool. The outcome will determine who controls licensing revenues and how this technology is commercialized.

Why it matters:
CRISPR has the potential to treat genetic diseases, improve agriculture, and transform diagnostics. But the patents behind it decide who profits from the gene revolution.

The bigger picture:
This battle isn’t just legal — it’s about who will shape the future of biotech.

#ExyIP #ExyIntellectualProperty #IPUpdate #IntellectualProperty #TrademarkLaw #IPknowledge